Lung cancer trial breakthrough
BioNTech reports experimental lung cancer drug nearly doubles overall survival in trial
Anonymous
Key Points
1
At the July 17, 2026 data cutoff, the trial had a median follow-up of 25.4 months; 45 patients received gotistobart monotherapy and 42 received docetaxel.
2
The survival comparison had a nominal p-value of 0.0295, and the updated findings were presented at the International Association for the Study of Lung Cancer’s 2026 World Conference on Lung Cancer.
3
Gotistobart is an investigational CTLA-4-targeting immunotherapy designed to selectively deplete regulatory T cells in the tumor microenvironment, rather than functioning as conventional chemotherapy.
4
The drug has received Fast Track Designation from the U.S. Food and Drug Administration for metastatic NSCLC, Orphan Drug Designation for squamous NSCLC, and Breakthrough Therapy Designation from China’s National Medical Products Administration.
5
The pivotal stage 2 portion of PRESERVE-003 is being conducted at more than 160 sites globally, while the stage 1 results had previously been published in Nature Medicine.
BioNTech and OncoC4 announced a major breakthrough in lung cancer treatment on July 17, 2026. Their experimental drug gotistobart nearly doubled survival time for patients with advanced squamous non-small cell lung cancer that had stopped responding to standard immunotherapy and chemotherapy. Patients taking gotistobart lived a median of 18.5 months compared to 10.0 months for those on docetaxel chemotherapy — a 85% improvement Yahoo Finance.
The trial included 87 patients split into two groups. The results showed gotistobart was safer too, with similar rates of serious side effects in both treatment arms. The drug works differently from traditional chemotherapy — it targets immune cells in tumors rather than attacking cancer cells directly Yahoo Finance.
How Gotistobart Works in the Tumor
Gotistobart is an immunotherapy that selectively depletes regulatory T cells inside the tumor microenvironment. These immune cells normally suppress the body's anti-cancer defenses. By removing them, the drug allows a patient's immune system to attack cancer more effectively Yahoo Finance.
This approach differs sharply from docetaxel, a conventional chemotherapy that directly kills dividing cells. The trial results suggest that this immune-focused strategy works better for patients whose tumors have become resistant to standard treatments Yahoo Finance.
Trial Results Show Statistically Significant Benefit
At the July 17, 2026 data cutoff, 45 patients received gotistobart and 42 received docetaxel. The median follow-up period was 25.4 months. The survival advantage had a p-value of 0.0295, meaning there is only a 3% chance the results occurred by random variation Yahoo Finance.
A hazard ratio of 0.56 means patients on gotistobart had 44% lower risk of death compared to docetaxel. Both groups experienced similar rates of serious adverse events, suggesting the new drug does not carry unacceptable toxicity risks Yahoo Finance.
Regulatory Path Fast-Tracked for Advanced Development
Gotistobart has already earned three important regulatory designations from health authorities. The U.S. FDA granted Fast Track and Breakthrough Therapy Designations. China's National Medical Products Administration also awarded Breakthrough Therapy Designation Yahoo Finance.
The pivotal second stage of PRESERVE-003 is now underway at more than 160 sites globally. BioNTech and OncoC4 presented these stage 1 results at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer in South Korea Yahoo Finance.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
51
Reach
64
A
AnonymousAuthor
